Antibody-Based Therapies for Colorectal Cancer
2005; AlphaMed Press; Volume: 10; Issue: 9 Linguagem: Inglês
10.1634/theoncologist.10-9-701
ISSN1549-490X
AutoresKi Y. Chung, Leonard B. Saltz,
Tópico(s)Hepatocellular Carcinoma Treatment and Prognosis
ResumoAbstract Learning Objectives After completing this course, the reader will be able to: Select the appropriate clinical use of cetuximab and bevacizumab in the treatment of metastatic colorectal cancer based on the currently available clinical trial data and known toxicities of each agent.Discuss the controversy over EGFR testing in colorectal cancer patients and the lack of predictive value of EGFR expression by IHC.List the relevant clinical questions regarding the use of targeted agents in colorectal cancer that remain to be addressed by clinical trials. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com The recent successful development of novel monoclonal antibodies that target key components of biologic pathways has expanded the armamentarium of treatment options for patients with colorectal cancer. Two targets in particular–the process of new blood vessel development, or angiogenesis, and the epidermal growth factor receptor and its signaling pathway–are exploited by the newest monoclonal antibodies that are available for use in colorectal cancer patients. This clinical review focuses on the defining role of the two most clinically advanced novel agents, bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA, http://www.gene.com) and cetuximab (Erbitux®; ImClone Systems, Inc., New York, http://www.imclone.com), in colorectal cancer.
Referência(s)